NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Abstract: Derivatives of 8-substituted xanthines which are used in the prophylactic or therapy of diseases or disorders which have a pruritic component.

Description: NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY FIELD OF INVENTION The present invention relates to compounds which are of use in the treatment and management of pruritis. BACKGROUND OF THE INVENTION Pruritis is a common symptom of many inflammatory skin diseases, notably psoriasis and atopic dermatitis. This symptom has historically been difficult to model. Recently, a behavioral model for peripherally evoked itch was published (Woodward et al., Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J. Pharmacol. Exp. Therap. 272:758- 765, 1995). This model has lead to additional modifications as will be shown herein. As little effective treatment for this condition exists, there remains a need for treatment, in this field, for compounds which are capable of anti-pruritic activity. SUMMARY OF THE INVENTION This invention relates to the novel use of PDE4 inhibitors, preferably compounds of Formula (I) for the prophylaxis, treatment and management of pruritis in a mammal, including humans, in need of such treatment, which method comprises administering to such mammal, an effective amount of a compound of Formula (I). The compounds of the present invention of Formula (I) are described herein. BRIEF DESCRIPTION OF THE DRAWINGS Figure I demonstrates the anti-pruritic activity of compound I. 1 ,3-di- cyclopropylmethyl-8-amino xanthine in an arachidonic acid induced pruritis model. DETAILED DESCRIPTION OF THE INVENTION The present invention has found that PDE4 inhibitors, as a class of compounds, regardless of structure possess anti-pruritis activity As pruritis is a key symptom of many different disease states, the use of PDE4 inhibitors in the managment of pruritic activity is of great value. While it is recognized that PDE4 compounds are of many different structural classes, they all share a common feature, inhibition of the PDE4 isoenzymes. A skilled .artisan, using well known and defined assays, will be able to determine if a compound is an inhibitor of the PDE4 isoenzymes, and be of use herein Suitable PDE4 compounds for use herein include, but are not limited to, those descπbed in WO 92/00968, PCT/US91/08229, WO 92/05175, WO 92/05176, WO 92/11260, WO 93/01014, PCT/US92/03613, WO 93/07111, PCT/US93/02045, WO 93/19748, WO 93/19750, WO 93/19751, WO 93/19747, WO 93/19749, WO 93/19720, WO 94/20079, WO 95/00139, WO 95/08581, WO 95/09308, WO 95/09623, WO 95/09836, WO 95/09624, WO 95/09837, WO 95/09627, WO 95/24381, WO 95/27692, WO 96/19995, WO 96/20158, WO 96/20153, WO 96/19980, WO 96/19988, WO96/19977, WO 96/20161, WO 96/20157, PCT/US95/16707, WO 96/20690, WO 96/20159, WO 96/19983, WO 96/19984, WO 96/19985, WO 96/19990, WO 96/19994, WO 96/20163, WO 96/20156, WO 96/19986, WO 96/20174, WO 96/19979, WO 96/20160 WO 96/20175, WO 96/19993, WO 96/20162, WO 96/19978, WO 96/23754, WO 96/36594, , WO 97/03945, US 5,734,051 and US 5,420, 154 Suitable assays for determination of PDE4 activity are also described in the above noted references, whose disclosures are incorporated by reference herein in their entirety A particular PDE4, CP 80633 is describ-sd in J.M. Hanifin et al. J. Invest. Dermatol. 107:51-56 (1996). Preferably, the method of use does net include the compound CP80633. The compounds of Formula (I) may also be used in association with the veteπnary treatment of mammals, other than in humans, in need of such treatment for pruritis Treatment, may be therapeutically or prophylactically in animals The compounds of the present invention of Formula (I), are descπbed in US Patent 5,734,05 1 and are represented by the structure wherein Rl and R 2 are each independently alkyl or a moiety of the formula -(CH 2 ) m -A, m is a number from 0 to 3, A is an unsubstituted or substituted cyclic hydrocarbon radical R3 is halogen, nitro, or -NR 4 R 5 ; R4 and R 5 are independently hydrogen, alkyl, alkylcarbonyl or together with the nitrogen to which they are attached forming an optionally substituted heterocyclic ring; and the pharmaceutically acceptable salts thereof. Preferably both Ri and R2 represent -(CH2) m -A. Preferably the A moiety represents a C 3 -8 cycloalkyl group, particularly a C3- 6 cycloalkyl and preferably unsubstituted. More preferably A is a cyclopropyl or cyclobutyl moiety. Preferably m is zero or one. Suitable optional substituent groups for any cyclic hydrocarbon include a Ci^alkyl moiety or halogen atom. A preferred group for Ri or R 2 is an alkyl group of 1 to 6 carbons, specifically methyl, ethyl, propyl or n-butyl. More preferred is n-butyl. When R 3 is halogen, the preferred substitution is bromine or chlorine When R3 is -NR 4 R 5 , and R 4 and R5 represent alkyl or alkylcarbonyl, it is preferred that one of R4 or R 5 is hydrogen Suitable heterocyclic groups include saturated or unsaturated heterocylic groups having single or fused rings, each ring having 5 to 7 ring atoms which ring atoms optionally comprise up to two additional hetero atoms selected from 0, N, or S. Preferred heterocyclic groups include single rings comprising 5 to 7 ring atoms, more preferably 5 to 6 ring atoms,and most preferably 6 ring atoms Preferred heterocyclic groups are pyrrolidinyl, piperidinyl, or morpholinyl rings Specifically exemplified compounds of Formula (I) are 1,3-d n-butyl-8-nitro xanthine; 1,3-d •cyclopropylmethyl-8-nitro xanthine, 1,3-d cyclobutylmethyl-8-nitro xanthine; 1,3-d cyclopentylmethyl-8-nitro xanthine; 1,3-d cyclohexylmethyl-8-nitro xanthine, 1,3-d n-butyl-8-amino xanthine; 1,3-d -cyclopropylmethyl-8-amino xanthine, 1,3-d -cyclobutylmethyl-8-amino xanthine, 1,3-d -cyclopentylmethyl-8-amino xanthine; 1,3-d -cyclohexylmethyl-8-amino xanthine, 1,3-d: -cyclopropyl-8-amino xanthine; 1,3-d -n-butyl-8-acetamido xanthine, - j 1,3-d n-butyl-8-chloro xanthine; 1,3-d -n-butyl-8-bromo xanthine; 1,3-d cyclopropylmethyl-8-chloro xanthine; 1,3-d cyclohexyl-8-chloro xanthine; 1,3-d n-butyl-8-piperidino xanthine; 1,3-d -cyclopropylmethyl-8-morpholino xanthine; 1,3-d -n-butyl-8-pyrrolidinyl xanthine; 1,3-d -cyclopropylmethyl-8-pyrrolidinyl xanthine; 1,3-d: cyclopropylmethyl-8-piperidinyl xanthine; 1,3-d -cyclohexylmethyl-8-piperidinyl xanthine; 1,3-d cyclohexylmethyl-8-bromo xanthine; and 1,3-d cyclohexyl-8-nitro xanthine; or the pharmaceutically acceptable salts thereof. The most preferred compound of Formula (I) for use in the method of this invention is l,3-di-cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof. By the term "alkyl" groups as used herein, alone or when used as part of another group (for example as in alkylcarbonyl) is meant to include both straight or branched chain radicals of 1 to 12 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, and the like. By the term "cyclic hydrocarbon", unless specified otherwise, as used herein is meant a single ring or a fused rings of 3 to 8 carbon atoms. Cyclic hydrocarbons may comprise up to 8 carbons in each ring. The term "cycloalkyl" or "cycloalkyl alkyl" as used herein is meant to be interchangeable with the term "cyclic hydrocarbon" Cycloalkyl and cycloalkyl-alkyl groups are meant to include, but not limited to cyclopropyl, cyclopropyl-methyl, cyclopentyl or cyclohexyl. By the term "halo" as used herein is meant all halogens, i.e.. chloro, fluoro, bromo and iodo. METHODS OF PREPARATION The preparation of the compounds of Formula (I) can be carried out by one of skill in the art according to the procedures outlined herein, and as described in Maschler et al.. Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent No. 5,734,051 whose entire disclosures are incorporated herein by reference in its entirety. METHODS OF TREATMENT The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can also be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or or unregulated pruritic activity. The compounds of Formula (I) may be used topically in the treatment or prophylaxis of topical disease states which have a pruritic component. The compounds of Formula (I) are disclosed in Maschler et al.. Great Britain Patent Application No. 8906792.0 filed on March 23, 1989, and US Patent 5,734,051 for the treatment of disorders associated with increased numbers of eosinophils, such as proliferative skin disease states, i.e. psoriasis, atopic dermatitis, non-specific dermititis, primary irritant contact dermatitis, allergic contact dermititis, or allergic disorders such as atopy, uticaria, eczema, rhinitis, serborrheic dermatitis, and mange in domestic animals. The compounds of Formula (I) are also disclosed in PCT/US91/08734, and PCT US93/01496 published as WO 93/06699 whose dislosures are incorporated herein by reference in its entirety, for the treatment of tumour necrosis mediated diseases. The compounds of Formula (I) may, be administered concurrently with another agents useful for the treatment or managment of pruritis, such as steroids. It will be recognized by one of skill in the art that the actual amount of a monokine activity interfering agent required for therapeutic effect will, of course, vary with the agent chosen, the route of administration desired, the nature and severity of the disease, and the particular condition of the mammal, specifically human, undergoing treatment, and is ultimately at the discretion of the physician. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the agent will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the agent given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. The compounds of Formula (I) may be administered orally (when active by this route), topically, parenterally or by inhalation in conventional dosage forms prepared by combining such agent with standard pharmaceutical earners according to conventional procedures in an amount sufficient to produce therapeutic activity The pharmaceutical earner employed can be readily determined by one of skill in the art who will recognize that such determination will depend upon vanous well- known factors such as the nature, quantity and character of the particular monokine activity mterfenng agent being employed and the form and route of administration desired The earners employed may be those desenbed elsewhere herein In order to use a compound of the Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition The pharmaceutical composition of the present invention will comprise an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable earner or diluent The compounds of Formula (I) are administered in conventional dosage forms prepared by combining a compound of Formula (I) in an amount sufficient to produce activity, respectively, with standard pharmaceutical earners according to conventional procedures These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropnate to the desired preparation The pharmaceutical earner employed may be, for example either a solid or liquid Exemplary of solid earners are lactose, terra alba, sucrose talc, gelatin, agar pectin, acacia, magnesium stearate, steanc acid and the like Exemplary of liquid earners are syrup, peanut oil, olive oil, polyethylene glycol, coconut oil, water and the like Similarly, the earner or diluent may include time delay mateπal well known to the art such as glyceryl monostearate or glyceryl distearate alone or with a wax Compounds of Formula (I) and their pharmaceutically acceptable salts can be employed in a wide vanety of pharmaceutical forms The preparation of a pharmaceutically acceptable salt will be determined by the nature of the compound itself, and can be prepared by conventional techniques readily available to one skilled in the art Thus, if a solid earner is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge The amount of solid earner will vary widely but preferably will be from about 25 mg to about 1 gram When a liquid earner is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, stenle injectable liquid such as an ampule or nonaqueous liquid suspension Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, polyethylene glycol, coconut oil, glycerine or water with a flavouring or colouring agent. The amount of a compound of Formula (I) required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the inflammatory condition and the animal undergoing treatment, and is ultimately at the discretion of the physician. The term 'parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyviny'pyrrolidoπc, lecithin, arachis oil, or sesame oil The daily dosage regimen for parenteral administration is suitably about 0 001 mg/Kg to 40 mg/Kg, preferably about 0 01 mg/Kg to 20 mg/Kg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base The compounds of Formula (I) may be administered orally The daily dosage regimen for oral administration is suitably about 1 mg/kg to 1 OOOmg day For administration the dosage is suitably about 001 mg/kg to 40mg/kg, preferably about 0 01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity The compounds of Formula (I) may also be administered by inhalation By "inhalation" is meant intranasal and oral inhalation administration Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The daily dosage regimen for inhalation administration is suitably about 001 mg/kg to 40mg/kg, preferably 0 01 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or tπchlorofluoromethane Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose The compounds of Formula (I) may also be administered topically Bv topical administration is meant non-systemic administration and includes the application of a compound of Formula (I) externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream The daily dosage regimen for topical administration is suitably about 001 mg/kg to lOOmg/kg, preferably 0 1 to 20 mg/Kg of a compound of formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base By systemic administration is meant oral, intravenous, intrapentoneal and intramuscular administration While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation The active ingredient may compnse, for topical administration, from 0 001% to 10% w/w e g from 1% to 2% by weight of the formulation although it may compnse as m u ch as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0 1% to 1% w/w of the formulation The topical formulations of the present invention comprise an active ingredient together with one or more acceptable carner(s) therefor and optionally any other therapeutic ιngredιent(s) The carπer(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deletenous to the recipient thereof Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose Drops according to the present invention may comprise steπle aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactencidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and steπlized by autoclaving or maintaining at 98-100°C for half an hour Alternatively, the solution may be sten zed by filtration and transfened to the container by an aseptic technique Examples of bactencidal and fungicidal agents suitable for inclusion in the drops are phenylmercuπc nitrate or acetate (0 002%), benzalkonium chlonde (0 01%) and chlorhexidme acetate (0 01%) Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol Lotions according to the present invention include those suitable for application to the skin or eye An eye lotion may compnse a stenle aqueous solution optionally containing a bactencide and may be prepared by methods similar to those for the preparation of drops Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moistuπzer such as glycerol or an oil such as castor oil or arachis oil Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application Thev may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery with a greasy or non-greasy basis The basis may compnse hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural oπgm such as almond, corn, arachis, castor or olive oil, wool fat or its denvatives, or a fatty acid such as stenc or oleic acid together with an alcohol such as propylene glycol or macrogols The formulation may incorporate any suitable surface active agent such as an anionic, catiomc or non-ionic surfactants such as sorbitan esters or polyoxyethylene denvatives thereof Suspending agents such as natural gums cellulose derivatives or inorganic materials such as silicaceous silicas and other ingredients such as lanolin, may also be included It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable earner or diluent is dictated by the amount of active ingredient, a compound of Formula (I), with which it is to be combined, the route of administration and other well-known vanables It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration and the particular patient being treated, and that such optimums can be determined by conventional techniques It will also be appreciated by one of skill in the art that the optimal course of treatment 1 e the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. FORMULATION EXAMPLES Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of liquid formulations are given below. 1 A solution containing a compound of Formula (I) is prepared by dissolving the compound in water, or other suitable carrier, with or without a preservative, such as benzoic acid, to deliver the desired amount of drug per use The compound is present in an amount from about lOμg to about 30 μg/ per ml of carrier 2 A solution containing a compound of Formula (I) is prepared by dissolving the compound in an amount from about 1 to about lOmg per ml of PEG 400 with or without BHA/BHT preservatives The solution can alternatively be filled into a soft gelatin capsule to prepare a solid oral dosage form or used as a syrup 3 A solid dosage form containing a compound of Formula (I), such as 1,3-di- cyclopropylmethyl-8-amino xanthine has been prepared by mixing 50mg of the compound with various concentration (mg) of mannitol, hydroxypropylmethylcellulose, calipharm, Starch 1500, and magnesium sterate (as a lubricant), to fill capsules of an appropriate size or the composition may, if desired, be compressed into tablets Various formulation of the ingredients are presented in Table 1 , numbered from 1 to 6 UTILITY EXAMPLES The method described in the Woodward et al manuscript, supra, served as the protoype for the mouse model which developed in the present invention The mouse model takes advantage of the cutaneous inflammatory response to arachidonic acid which is preceeded by scratching and rubbing behavior indicative of pruritis.. Briefly. Balb/c mice were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 min period. The data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determined using Student's t-test. The biochemical pharmacology of the inflammatory response to arachidonic acid has implicated mast cell degranulation and eicosanoid inflammatory mediator release (e.g. leukotrienes and prostanoids). Tachykinins and platelet activating factor may also be involved in this response. The anti-inflammatory activity of phosphodiesterase type 4 (PDE4) inhibitors was also demonstrated using arachidonic acid (Griswold, D.E.et al., Pharmacology of the pyrroloimidazole, SK&F 105809. Antiinflammatoiy activity and inhibition of mediator production in vivo. Biochemical Pharmacology 42:825-831, 1991) whose disclosure is incorporated by reference herein in its entirety. Specific Methods: Male Balb/c mice (n=6/treatment group) weighing 19-23 grams were administered a topical dose of arachidonic acid (2 mg/ear) in 20 ul cold acetone to the left ear. Immediately after that application, vehicle or test compound was applied to the same ear in a volume of 25 ul. Doses varied from 5 to 1000 ug/ear. The treated mice were then placed individually into 4L beakers. After a 2 min accommodation period, the episodes of scratching and head shaking were counted over a 10 min period. The data were analysed by calculating the mean and standard error. A statistical difference in the mean values was determin-ed using Student's t-test. It was of interest, therefore to determine if PDE4 inhibitors of different structural classes would demonstrate anti-pruritic activity in this model. As indicated below, three such PDE4 inhibitors did demonstrate signficant anti-pruritic activity. Topical Anti- ruritic Acitivit of PDE4 Inhibitors ***, Statistically significant at a p < 0.001 versus vehicle control, BRL 61063 is the same as Compound I. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth. The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims: What is Claimed is 1. A method of treating pruritis in a mammal in need thereof which comprises administering to such mammal an effective amount of a compound of a PDE4 inhibitor, other than CP 80633. 2. The method according to Claim 1 wherein the PDE4 inhibitor is a compound of the formula: wherein Ri and R 2 each independently represent alkyl or -(CH2) - A; m represents zero or an integer 1, 2 or 3; A represents a substituted or unsubstituted cyclic hydrocarbon radical; R 3 represents a halogen atom, a nitro group, or a group -NR 4 R 5 ; R 4 and R 5 each independently represent hydrogen, alkyl or alkylcarbonyl; or R 4 and R 5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic group; and the pharmaceutically acceptable salts thereof. 3. The method according to claim 2, wherein R \ represents -(CH 2 )m-A. 4. The method according to claim 2, wherein Ri and R 2 both independently represent -(CH 2 ) m -A. 5. The method according to claim 4 wherein A represents a substituted or unsubstituted C 3 . 8 cycloalkyl group. 6. The method according to claim 4, wherein m represents 1. 7. The method according to claim 6, wherein A represents a substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group. 8. The method according to claim 7, wherein A represents a cyclopropyl group or a cyclobutyl group. 9 The method according to claim 8, wherein R3 is nitro, or -NR4R 5 wherein R 4 is hydrogen and R 5 is hydrogen or alkylcarbonyl 10 The method according to claim 9, wherein R 4 or R5 is hydrogen 11 The method according to claim 10, wherein A represents a cyclopropyl group 12. The method according to claim 2 wherein the compound is selected from the group consisting of 1,3-di- - nn--bbuuttyyll--88--nniittrroo xxaanntthhiinnee,, 1,3-di- - ccyycclloopprrooppyyllmmeetthhyyll--88--nniittrroo xxaanntthhiirn ee,, 1,3-di- -c cyycclloobbuuttyyllmmeetthhyyll--88--nniittrroo xxaanntthhiinnee, 1,3-di- -c cyyccllooppeennttyyllmmeetthhyyll--88--nniittrroo xxaanntthhiinn ee,, 1,3-di- -c cyycclloohheexxyyllmmeetthhyyll--88--nniittrroo xxaanntthhiinnee, 1,3-di- -n n--bbuuttyyll--88--aammiinnoo xxaanntthhiinnee,, 1,3-di- -c cyycclloopprrooppyyllmmeetthhyyll--88--aammiinnoo xxaanntthhii nnee,, 1,3-di- -c cyycclloobbuutty3'llmmeetthhyyll--88--aammiinnoo xxaanntthhiinn ee,, 1 ,3-di- -c cyyccllooppeennttyyllmmeetthhyyll--88--aammiinnoo xxaanntthhiin nee,, 1,3-di- -c Dyycclloohheexxyyllmmeetthhyyll--88--aammiinnoo xxaanntthhiinn ee,, 1,3-di- -c :yycclloopprrooppyyll--88--aammiinnoo xxaanntthhiinnee,, 1,3-di- -n ι--bbuuttyyll--88--aacceettaammiiddoo xxaanntthhiinnee,, 1,3-di- -ιn ι--bbuuttyyll--88--cchhlloorroo xxaanntthhiinnee,, 1,3-di- -ιn ι--bbuuttyyll--88--bbrroommoo xxaanntthhiinnee,, l,3-di- -<c ;yycclloopprrooppyyllmmeetthhyyll--88--cchhlloorroo xxaanntthhi mnee,, l,3-dι- -(c ;yycclloohheexxyyll--88--cchhlloorroo xxaanntthhiinnee,, 1,3-di- -ιn ι--bbuuttyyll--88--ppiippeerriiddiinnoo xxaanntthhiinnee,, 1,3-di- -cc ;yycclloopprrooppyyllmmeetthhyyll--88--mmoorφphhoolliinnoo > x caanntthhiinnee., 1,3-di- -ιn ι--bbuuttyyll--88--ppyyrrrroolliiddiinnyyll xxaanntthhiinnee,, 1,3-di- -cc :yycclloopprrooppyyllmmeetthhyyll--88--ppyyrrrroolliiddiinnyyll > x caanntthhiinnee,, 1,3-di- -cc :yycclloopprrooppyyllmmeetthhyyll--88--ppiippeeririddiinnyyll xx£a inntthhiinnee,, 1,3-di- -cc ;yycclloohheexxyyllmmeetthhyyll--88--ppiippeeririddiinnyyll xxaain itthhiinnee,, 1,3-di- -cc ;yycclloohheexxyyllmmeetthhyyll--88--bbrroommoo xxaanntthhiirn lee,, aanndd 1,3-di- -cc ;yycclloohheexxyyll--88--mmttrroo xxaanntthhiinnee,, oorr iiff a a pppprrooppririaattee,, aa D phhaarrmm∑a icceeuuttiiccaallllyy aacc ;cceeppttaabbllee salt thereof 13 The method according to Claim 2 wherein the compound is 1,3-di- cyclopropylmethyl-8-amino xanthine or a pharmaceutically acceptable salt thereof 14 The method of Claim 2 or 13 wherein the compound is administered orally, parenterally, topically or by inhalation 15 The method according to Claim 14 wherein the compound is administered topically 16 The method according to Claim 1 wherein the compound is administered topically with an effective amount of a second anti-pruritic compound 17 The method according to Claim 1 wherein the compound is described in WO 92/00968, PCT/US91/08229, WO 92/05175, WO 92/05176, WO 92/11260, WO 93/01014, PCT/US92/03613, WO 93/07111, PCT/US93/02045, WO 93/19748, WO 93/19750, WO 93/19751, WO 93/19747, WO 93/19749, WO 93/19720, WO 94/20079, WO 95/00139, WO 95/08581, WO 95/09308, WO 95/09623, WO 95/09836, WO 95/09624, WO 95/09837, WO 95/09627, WO 95/24381, WO 95/27692, WO 96/19995, WO 96/20158, WO 96/20153, WO 96/19980, WO 96/19988, WO96/19977, WO 96/20161, WO 96/20157, PCT/US95/ 16707, WO 96/20690, WO 96/20159, WO 96/19983, WO 96/19984, WO 96/19985, WO 96/19990, WO 96/19994, WO 96/20163, WO 96/20156, WO 96/19986, WO 96/20174, WO 96/19979, WO 96/20160 WO 96/20175, WO 96/19993, WO 96/20162, WO 96/19978, WO 96/23754, WO 96/36594, , WO 97/03945, US 5,734,051 and US 5,420, 154 18 A method of treating pruritis in a mammal in need thereof which comprises administering to such mammal an effective amount of the compound 1,3- di-cyclopropylmethyl-8-amino xanthine, or a pharmaceutically acceptable salt thereof 19 The method of Claim 18 wherein the compound is administered orally, parenterally, topically or by inhalation 20 The method according to Claim 19 wherein the compound is administered topically 21. The method according to Claim 18 wherein the compound is administered topically with an effective amount of a second anti-pruritic compound. 22. The method according to Claim 21 wherein the second anti-prutitic compound is a steroid.

Inventors: CHRISTENSEN SIEGFRIED BENJAMIN, GRISWOLD DON E, CHRISTENSEN, SIEGFRIED, BENJAMIN, IV, GRISWOLD, DON, E.
Applicants: CHRISTENSEN SIEGFRIED B, GRISWOLD DON E, SMITHKLINE BEECHAM CORP, CHRISTENSEN, SIEGFRIED, BENJAMIN, IV, GRISWOLD, DON, E., SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: A61K31
IPC codes: A61K31, A61K45, A61P17, C07D473